

TABLE 1. Clinical studies evaluating immunotherapy in MSS CRC.

Study	Phase	Setting	Treatment	Results
IMblaze 370	III	Locally advanced or mCRC	Atezolizumab +- cobimetinib versus regorafenib.	No survival benefit with atezolizumab in patients with MSS CRC
KEYNOTE-016	II	mCRC	Pembrolizumab	No clinical benefit in patients with MSS CRC
CO.26	II	mCRC	Durvalumab + Tremelimumab	Improved survival benefit in patients with MSS CRC
REGONIVO	Ib	Locally advanced or mCRC	Regorafenib + Nivolumab	Promising results in patients with MSS CRC
NICHE	II	Neoadjuvant setting- early stage MSS CRC	Nivolumab + Ipilimumab	Major pathological response in 26% of patients with MSS CRC
NEST-1	II	Neoadjuvant setting- resectable CRC	Botensilimab+ Balstilimab	Promising results in patients with MSS CRC
FFCD 1703-POCHI trial	II	unresectable pMMR/MSS mCRC	Pembrolizumab+ capecitabine plus oxaliplatin (CAPOX)+ bevacizumab	Promising results in patients with MSS CRC